Investigator site: Saint Joseph Hospital, Marseille: M. Bourlière, V. Oules; Haut Lévêque Hospital, Pessac: P. Couzigou, J. Foucher, L. Castéra, P. Trimoulet, J. Berthet, N. Le Provost; Brabois Hospital, Vandoeuvre Les Nancy: J.P. Bronowicki, L. Chone, L. Arowas, S. Khaled-Jousselin; Pitié-Salpétrière Hospital, Paris: Th. Poynard, Y. Benhammou, V. Ratziu, C. Blot; Albert Michallon Hospital, Grenoble: J.P. Zarski, V. Leroy, A. Plagès; Beaujon Hospital, Clichy: P. Marcellin, T. Asselah; Saint André Hospital, Bordeaux: C. Balabaud, P.H. Bernard, J. Foucher. Steering Committee: L. Allain, P.H. Bernard, M. Bourlière, J.P. Bronowicki, G. Chêne, P. Couzigou, V. Leroy, P. Marcellin, S. Pérusat, P. Trimoulet, J.P. Zarski. Clinical Trials Unit/INSERM U897, Bordeaux School of Public Health (ISPED), University Victor Segalen Bordeaux 2: A. André, V. Boilet, G. Chêne, S. Pérusat. Sponsor, ANRS: L. Allain, A. Metro, C. Paul, N. Squalli.
Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy*)
Article first published online: 27 OCT 2010
Copyright © 2010 Wiley-Liss, Inc.
Journal of Medical Virology
Volume 82, Issue 12, pages 2027–2031, December 2010
How to Cite
Halfon, P., Pérusat, S., Bourlière, M., Bronowicki, J.-P., Trimoulet, P., Benhamou, Y., Leroy, V., Marcellin, P., Foucher, J., Penaranda, G., Chêne, G. and Couzigou, P. (2010), Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy*). J. Med. Virol., 82: 2027–2031. doi: 10.1002/jmv.21909
- Issue published online: 27 OCT 2010
- Article first published online: 27 OCT 2010
- Manuscript Accepted: 14 JUN 2010
- ANRS (French National Agency for Research on AIDS and Viral Hepatitis)
- second-line treatment;
- neutralizing antibody;
- hepatitis C virus;
A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)-interferon (IFN)-α-2a + ribavirin (RIBA) may be explained by neutralizing antibodies to IFN-α-2a. The aim of this study was to assess neutralizing antibodies to IFN-α-2a and IFN levels in non-responder patients who were re-treated by PEG IFN-α-2a and RIBA for 12 weeks. Non-responders to a first-line treatment of PEG IFN-α-2a + RIBA were included for treatment with PEG IFN-α-2a (180 µg/week) + RIBA (1,000 mg/day if <75 kg, 1,200 mg otherwise) for 48 weeks. HCV RNA was measured at week 12. IFN levels and neutralizing antibodies to IFN-α-2a were measured retrospectively on stored sera at baseline and weeks 4 and 12, using a quantitative sandwich ELISA for neutralizing antibodies to IFN-α-2a. Twenty-three patients were non-responders and 19 patients were responders at week 12 of the initial phase of the second-line treatment. Non-responders and responders did not differ statistically: baseline age (median age 47 vs. 50 years), HCV RNA (median 6.8 vs. 6.4 log10 copies/ml), gender (70% vs. 73% males), genotype (genotype 1: 91% vs. 80%). The median IFN-α-2a levels (pg/ml) at weeks 0, 4, and 12 (interquartile range) did not differ between the 19 responders to initial phase of second-line treatment and the 23 non-responders: <3.3 (<3.3–371.4), 1457.3 (106.8–3284.8), and 1,652 (90.8–5,000); 84.5 (3.3–277.4), 1407.4 (120.2–2443.4), and 1620.1 (120.2–2287.1), respectively. Among non-selected consecutive non-responder patients, re-treatment with PEG IFN-α-2a + RIBA is associated with virological response regardless of the presence of antibody-mediated resistance to conventional IFN treatment. J. Med. Virol. 82:2027–2031, 2010. © 2010 Wiley-Liss, Inc.